ATC code L01: Difference between revisions

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
VisualWikitext
imported>Whywhenwhohow
2025 changes
 
imported>Josvebot
m v2.05b - Fix errors for CW project (Unicode control characters)
 
Line 2: Line 2:
{{ATC codes lead|L|01|Antineoplastic agents|vet=add}}
{{ATC codes lead|L|01|Antineoplastic agents|vet=add}}


=={{anchor|L01A}}L01A Alkylating agents==
==<span class="anchor" id="L01A"></span>L01A Alkylating agents==


==={{anchor|L01AA}}L01AA Nitrogen mustard analogues===
===<span class="anchor" id="L01AA"></span>L01AA Nitrogen mustard analogues===
:L01AA01 [[Cyclophosphamide]]
:L01AA01 [[Cyclophosphamide]]
:L01AA02 [[Chlorambucil]]
:L01AA02 [[Chlorambucil]]
Line 15: Line 15:
:L01AA10 [[Melphalan flufenamide]]
:L01AA10 [[Melphalan flufenamide]]


==={{anchor|L01AB}}L01AB Alkyl sulfonates===
===<span class="anchor" id="L01AB"></span>L01AB Alkyl sulfonates===
:L01AB01 [[Busulfan]]
:L01AB01 [[Busulfan]]
:L01AB02 [[Treosulfan]]
:L01AB02 [[Treosulfan]]
:L01AB03 [[Mannosulfan]]
:L01AB03 [[Mannosulfan]]


==={{anchor|L01AC}}L01AC Ethylene imines===
===<span class="anchor" id="L01AC"></span>L01AC Ethylene imines===
:L01AC01 [[Thiotepa]]
:L01AC01 [[Thiotepa]]
:L01AC02 [[Triaziquone]]
:L01AC02 [[Triaziquone]]
:L01AC03 [[Carboquone]]
:L01AC03 [[Carboquone]]


==={{anchor|L01AD}}L01AD Nitrosoureas===
===<span class="anchor" id="L01AD"></span>L01AD Nitrosoureas===
:L01AD01 [[Carmustine]]
:L01AD01 [[Carmustine]]
:L01AD02 [[Lomustine]]
:L01AD02 [[Lomustine]]
Line 35: Line 35:
:L01AD08 [[Uramustine]]
:L01AD08 [[Uramustine]]


==={{anchor|L01AG}}L01AG Epoxides===
===<span class="anchor" id="L01AG"></span>L01AG Epoxides===
:L01AG01 [[Etoglucid]]
:L01AG01 [[Etoglucid]]


==={{anchor|L01AX}}L01AX Other alkylating agents===
===<span class="anchor" id="L01AX"></span>L01AX Other alkylating agents===
:L01AX01 [[Mitobronitol]]
:L01AX01 [[Mitobronitol]]
:L01AX02 [[Pipobroman]]
:L01AX02 [[Pipobroman]]
Line 44: Line 44:
:L01AX04 [[Dacarbazine]]
:L01AX04 [[Dacarbazine]]


=={{anchor|L01B}}L01B Antimetabolites==
==<span class="anchor" id="L01B"></span>L01B Antimetabolites==


==={{anchor|L01BA}}L01BA Folic acid analogues===
===<span class="anchor" id="L01BA"></span>L01BA Folic acid analogues===
:L01BA01 [[Methotrexate]]
:L01BA01 [[Methotrexate]]
:L01BA03 [[Raltitrexed]]
:L01BA03 [[Raltitrexed]]
Line 52: Line 52:
:L01BA05 [[Pralatrexate]]
:L01BA05 [[Pralatrexate]]


==={{anchor|L01BB}}L01BB Purine analogues===
===<span class="anchor" id="L01BB"></span>L01BB Purine analogues===
:L01BB02 [[Mercaptopurine]]
:L01BB02 [[Mercaptopurine]]
:L01BB03 [[Tioguanine]]
:L01BB03 [[Tioguanine]]
Line 61: Line 61:
:QL01BB90 [[Rabacfosadine]]
:QL01BB90 [[Rabacfosadine]]


==={{anchor|L01BC}}L01BC Pyrimidine analogues===
===<span class="anchor" id="L01BC"></span>L01BC Pyrimidine analogues===
:L01BC01 [[Cytarabine]]
:L01BC01 [[Cytarabine]]
:L01BC02 [[Fluorouracil]]
:L01BC02 [[Fluorouracil]]
Line 76: Line 76:
:L01BC59 [[Trifluridine]], combinations
:L01BC59 [[Trifluridine]], combinations


=={{anchor|L01C}}L01C Plant alkaloids and other natural products==
==<span class="anchor" id="L01C"></span>L01C Plant alkaloids and other natural products==


==={{anchor|L01CA}}L01CA Vinca alkaloids and analogues===
===<span class="anchor" id="L01CA"></span>L01CA Vinca alkaloids and analogues===
:L01CA01 [[Vinblastine]]
:L01CA01 [[Vinblastine]]
:L01CA02 [[Vincristine]]
:L01CA02 [[Vincristine]]
Line 86: Line 86:
:L01CA06 [[Vintafolide]]
:L01CA06 [[Vintafolide]]


==={{anchor|L01CB}}L01CB Podophyllotoxin derivatives===
===<span class="anchor" id="L01CB"></span>L01CB Podophyllotoxin derivatives===
:L01CB01 [[Etoposide]]
:L01CB01 [[Etoposide]]
:L01CB02 [[Teniposide]]
:L01CB02 [[Teniposide]]


==={{anchor|L01CC}}L01CC Colchicine derivatives===
===<span class="anchor" id="L01CC"></span>L01CC Colchicine derivatives===
:L01CC01 [[Demecolcine]]
:L01CC01 [[Demecolcine]]


==={{anchor|L01CD}}L01CD Taxanes===
===<span class="anchor" id="L01CD"></span>L01CD Taxanes===
:L01CD01 [[Paclitaxel]]
:L01CD01 [[Paclitaxel]]
:L01CD02 [[Docetaxel]]
:L01CD02 [[Docetaxel]]
Line 100: Line 100:
:L01CD51 Paclitaxel and [[encequidar]]
:L01CD51 Paclitaxel and [[encequidar]]


==={{anchor|L01CE}}L01CE Topoisomerase 1 (TOP1) inhibitors===
===<span class="anchor" id="L01CE"></span>L01CE Topoisomerase 1 (TOP1) inhibitors===
:L01CE01 [[Topotecan]]
:L01CE01 [[Topotecan]]
:L01CE02 [[Irinotecan]]
:L01CE02 [[Irinotecan]]
Line 106: Line 106:
:L01CE04 [[Belotecan]]
:L01CE04 [[Belotecan]]


==={{anchor|L01CX}}L01CX Other plant alkaloids and natural products===
===<span class="anchor" id="L01CX"></span>L01CX Other plant alkaloids and natural products===
:L01CX01 [[Trabectedin]]
:L01CX01 [[Trabectedin]]


=={{anchor|L01D}}L01D Cytotoxic antibiotics and related substances==
==<span class="anchor" id="L01D"></span>L01D Cytotoxic antibiotics and related substances==


==={{anchor|L01DA}}L01DA Actinomycines===
===<span class="anchor" id="L01DA"></span>L01DA Actinomycines===
:L01DA01 [[Dactinomycin]]
:L01DA01 [[Dactinomycin]]


==={{anchor|L01DB}}L01DB Anthracyclines and related substances===
===<span class="anchor" id="L01DB"></span>L01DB Anthracyclines and related substances===
:L01DB01 [[Doxorubicin]]
:L01DB01 [[Doxorubicin]]
:L01DB02 [[Daunorubicin]]
:L01DB02 [[Daunorubicin]]
Line 127: Line 127:
:L01DB11 [[Pixantrone]]
:L01DB11 [[Pixantrone]]


==={{anchor|L01DC}}L01DC Other cytotoxic antibiotics===
===<span class="anchor" id="L01DC"></span>L01DC Other cytotoxic antibiotics===
:L01DC01 [[Bleomycin]]
:L01DC01 [[Bleomycin]]
:L01DC02 [[Plicamycin]]
:L01DC02 [[Plicamycin]]
Line 134: Line 134:
:L01DC05 [[Utidelone]]
:L01DC05 [[Utidelone]]


=={{anchor|L01E}}L01E Protein kinase inhibitors==
==<span class="anchor" id="L01E"></span>L01E Protein kinase inhibitors==


==={{anchor|L01EA}}L01EA BCR-ABL tyrosine kinase inhibitors===
===<span class="anchor" id="L01EA"></span>L01EA BCR-ABL tyrosine kinase inhibitors===
:L01EA01 [[Imatinib]]
:L01EA01 [[Imatinib]]
:L01EA02 [[Dasatinib]]
:L01EA02 [[Dasatinib]]
Line 144: Line 144:
:L01EA06 [[Asciminib]]
:L01EA06 [[Asciminib]]


==={{anchor|L01EB}}L01EB Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors===
===<span class="anchor" id="L01EB"></span>L01EB Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors===
:L01EB01 [[Gefitinib]]
:L01EB01 [[Gefitinib]]
:L01EB02 [[Erlotinib]]
:L01EB02 [[Erlotinib]]
Line 156: Line 156:
:L01EB10 [[Mobocertinib]]
:L01EB10 [[Mobocertinib]]
:L01EB11 [[Aumolertinib]]
:L01EB11 [[Aumolertinib]]
:L01EB12 [[Firmonertinib]]


==={{anchor|L01EC}}L01EC B-Raf serine-threonine kinase (BRAF) inhibitors===
===<span class="anchor" id="L01EC"></span>L01EC B-Raf serine-threonine kinase (BRAF) inhibitors===
:L01EC01 [[Vemurafenib]]
:L01EC01 [[Vemurafenib]]
:L01EC02 [[Dabrafenib]]
:L01EC02 [[Dabrafenib]]
:L01EC03 [[Encorafenib]]
:L01EC03 [[Encorafenib]]
:L01EC04 [[Tovorafenib]]


==={{anchor|L01ED}}L01ED Anaplastic lymphoma kinase (ALK) inhibitors===
===<span class="anchor" id="L01ED"></span>L01ED Anaplastic lymphoma kinase (ALK) inhibitors===
:L01ED01 [[Crizotinib]]
:L01ED01 [[Crizotinib]]
:L01ED02 [[Ceritinib]]
:L01ED02 [[Ceritinib]]
Line 169: Line 171:
:L01ED05 [[Lorlatinib]]
:L01ED05 [[Lorlatinib]]


==={{anchor|L01EE}}L01EE Mitogen-activated protein kinase (MEK) inhibitors===
===<span class="anchor" id="L01EE"></span>L01EE Mitogen-activated protein kinase (MEK) inhibitors===
:L01EE01 [[Trametinib]]
:L01EE01 [[Trametinib]]
:L01EE02 [[Cobimetinib]]
:L01EE02 [[Cobimetinib]]
Line 175: Line 177:
:L01EE04 [[Selumetinib]]
:L01EE04 [[Selumetinib]]
:L01EE05 [[Mirdametinib]]
:L01EE05 [[Mirdametinib]]
:L01EE06 [[Tunlametinib]]


==={{anchor|L01EF}}L01EF Cyclin-dependent kinase (CDK) inhibitors===
===<span class="anchor" id="L01EF"></span>L01EF Cyclin-dependent kinase (CDK) inhibitors===
:L01EF01 [[Palbociclib]]
:L01EF01 [[Palbociclib]]
:L01EF02 [[Ribociclib]]
:L01EF02 [[Ribociclib]]
:L01EF03 [[Abemaciclib]]
:L01EF03 [[Abemaciclib]]


==={{anchor|L01EG}}L01EG Mammalian target of rapamycin (mTOR) kinase inhibitors===
===<span class="anchor" id="L01EG"></span>L01EG Mammalian target of rapamycin (mTOR) kinase inhibitors===
:L01EG01 [[Temsirolimus]]
:L01EG01 [[Temsirolimus]]
:L01EG02 [[Everolimus]]
:L01EG02 [[Everolimus]]
Line 187: Line 190:
:L01EG04 [[Sirolimus]]
:L01EG04 [[Sirolimus]]


==={{anchor|L01EH}}L01EH Human epidermal growth factor receptor 2 (HER2) tyrosine kinase inhibitors===
===<span class="anchor" id="L01EH"></span>L01EH Human epidermal growth factor receptor 2 (HER2) tyrosine kinase inhibitors===
:L01EH01 [[Lapatinib]]
:L01EH01 [[Lapatinib]]
:L01EH02 [[Neratinib]]
:L01EH02 [[Neratinib]]
:L01EH03 [[Tucatinib]]
:L01EH03 [[Tucatinib]]
:L01EH04 [[Zongertinib]]
:L01EH05 [[Mifanertinib]]
:L01EH06 [[Sevabertinib]]


==={{anchor|L01EJ}}L01EJ Janus-associated kinase (JAK) inhibitors===
===<span class="anchor" id="L01EJ"></span>L01EJ Janus-associated kinase (JAK) inhibitors===
:L01EJ01 [[Ruxolitinib]]
:L01EJ01 [[Ruxolitinib]]
:L01EJ02 [[Fedratinib]]
:L01EJ02 [[Fedratinib]]
Line 198: Line 204:
:L01EJ04 [[Momelotinib]]
:L01EJ04 [[Momelotinib]]


==={{anchor|L01EK}}L01EK Vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitors===
===<span class="anchor" id="L01EK"></span>L01EK Vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitors===
:L01EK01 [[Axitinib]]
:L01EK01 [[Axitinib]]
:L01EK02 [[Cediranib]]
:L01EK02 [[Cediranib]]
:L01EK03 [[Tivozanib]]
:L01EK03 [[Tivozanib]]
:L01EK04 [[Fruquintinib]]
:L01EK04 [[Fruquintinib]]
:L01EK05 [[Rivoceranib]]


==={{anchor|L01EL}}L01EL Bruton's tyrosine kinase (BTK) inhibitors===
===<span class="anchor" id="L01EL"></span>L01EL Bruton's tyrosine kinase (BTK) inhibitors===
:L01EL01 [[Ibrutinib]]
:L01EL01 [[Ibrutinib]]
:L01EL02 [[Acalabrutinib]]
:L01EL02 [[Acalabrutinib]]
Line 212: Line 219:
:L01EL06 [[Tirabrutinib]]
:L01EL06 [[Tirabrutinib]]


==={{anchor|L01EM}}L01EM Phosphatidylinositol-3-kinase (Pi3K) inhibitors===
===<span class="anchor" id="L01EM"></span>L01EM Phosphatidylinositol-3-kinase (Pi3K) inhibitors===
:L01EM01 [[Idelalisib]]
:L01EM01 [[Idelalisib]]
:L01EM02 [[Copanlisib]]
:L01EM02 [[Copanlisib]]
Line 218: Line 225:
:L01EM04 [[Duvelisib]]
:L01EM04 [[Duvelisib]]
:L01EM05 [[Parsaclisib]]
:L01EM05 [[Parsaclisib]]
:L01EM06 [[Inavolisib]]


==={{anchor|L01EN}}L01EN Fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitors===
===<span class="anchor" id="L01EN"></span>L01EN Fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitors===
:L01EN01 [[Erdafitinib]]
:L01EN01 [[Erdafitinib]]
:L01EN02 [[Pemigatinib]]
:L01EN02 [[Pemigatinib]]
Line 225: Line 233:
:L01EN04 [[Futibatinib]]
:L01EN04 [[Futibatinib]]


==={{anchor|L01EX}}L01EX Other protein kinase inhibitors===
===<span class="anchor" id="L01EP"></span>L01EP Cellular-mesenchymal-epithelial transition factor (c-MET) kinase inhibitors===
:L01EP01 [[Capmatinib]]
:L01EP02 [[Tepotinib]]
:L01EP03 [[Savolitinib]]
 
===<span class="anchor" id="L01EX"></span>L01EX Other protein kinase inhibitors===
:L01EX01 [[Sunitinib]]
:L01EX01 [[Sunitinib]]
:L01EX02 [[Sorafenib]]
:L01EX02 [[Sorafenib]]
Line 241: Line 254:
:L01EX14 [[Entrectinib]]
:L01EX14 [[Entrectinib]]
:L01EX15 [[Pexidartinib]]
:L01EX15 [[Pexidartinib]]
:L01EX17 [[Capmatinib]]
:L01EX18 [[Avapritinib]]
:L01EX18 [[Avapritinib]]
:L01EX19 [[Ripretinib]]
:L01EX19 [[Ripretinib]]
:L01EX21 [[Tepotinib]]
:L01EX22 [[Selpercatinib]]
:L01EX22 [[Selpercatinib]]
:L01EX23 [[Pralsetinib]]
:L01EX23 [[Pralsetinib]]
Line 252: Line 263:
:L01EX27 [[Capivasertib]]
:L01EX27 [[Capivasertib]]
:L01EX28 [[Repotrectinib]]
:L01EX28 [[Repotrectinib]]
:L01EX29 [[Vimseltinib]]
:QL01EX90 [[Toceranib]]
:QL01EX90 [[Toceranib]]


=={{anchor|L01F}}L01F Monoclonal antibodies and antibody drug conjugates==
==<span class="anchor" id="L01F"></span>L01F Monoclonal antibodies and antibody drug conjugates==


==={{anchor|L01FA}}L01FA CD20 (clusters of differentiation 20) inhibitors===
===<span class="anchor" id="L01FA"></span>L01FA CD20 (clusters of differentiation 20) inhibitors===
:L01FA01 [[Rituximab]]
:L01FA01 [[Rituximab]]
:L01FA02 [[Ofatumumab]]
:L01FA02 [[Ofatumumab]]
:L01FA03 [[Obinutuzumab]]
:L01FA03 [[Obinutuzumab]]


==={{anchor|L01FB}}L01FB CD22 (clusters of differentiation 22) inhibitors===
===<span class="anchor" id="L01FB"></span>L01FB CD22 (clusters of differentiation 22) inhibitors===
:L01FB01 [[Inotuzumab ozogamicin]]
:L01FB01 [[Inotuzumab ozogamicin]]
:L01FB02 [[Moxetumomab pasudotox]]
:L01FB02 [[Moxetumomab pasudotox]]


==={{anchor|L01FC}}L01FC CD38 (clusters of differentiation 38) inhibitors===
===<span class="anchor" id="L01FC"></span>L01FC CD38 (clusters of differentiation 38) inhibitors===
:L01FC01 [[Daratumumab]]
:L01FC01 [[Daratumumab]]
:L01FC02 [[Isatuximab]]
:L01FC02 [[Isatuximab]]


==={{anchor|L01FD}}L01FD HER2 (human epidermal growth factor receptor 2) inhibitors===
===<span class="anchor" id="L01FD"></span>L01FD HER2 (human epidermal growth factor receptor 2) inhibitors===
:L01FD01 [[Trastuzumab]]
:L01FD01 [[Trastuzumab]]
:L01FD02 [[Pertuzumab]]
:L01FD02 [[Pertuzumab]]
Line 278: Line 290:
:L01FD07 [[Zanidatamab]]
:L01FD07 [[Zanidatamab]]


==={{anchor|L01FE}}L01FE EGFR (epidermal growth factor receptor) inhibitors===
===<span class="anchor" id="L01FE"></span>L01FE EGFR (epidermal growth factor receptor) inhibitors===
:L01FE01 [[Cetuximab]]
:L01FE01 [[Cetuximab]]
:L01FE02 [[Panitumumab]]
:L01FE02 [[Panitumumab]]
:L01FE03 [[Necitumumab]]
:L01FE03 [[Necitumumab]]


==={{anchor|L01FF}}L01FF PD-1/PDL-1 (programmed cell death protein 1/ death ligand 1) inhibitors===
===<span class="anchor" id="L01FF"></span>L01FF PD-1/PDL-1 (programmed cell death protein 1/ death ligand 1) inhibitors===
:L01FF01 [[Nivolumab]]
:L01FF01 [[Nivolumab]]
:L01FF02 [[Pembrolizumab]]
:L01FF02 [[Pembrolizumab]]
Line 297: Line 309:
:L01FF12 [[Serplulimab]]
:L01FF12 [[Serplulimab]]
:L01FF13 [[Toripalimab]]
:L01FF13 [[Toripalimab]]
:L01FF14 [[Camrelizumab]]
:L01FF15 [[Envafolimab]]
:L01FF16 [[Sasanlimab]]


==={{anchor|L01FG}}L01FG VEGF/VEGFR (vascular endothelial growth factor) inhibitors===
===<span class="anchor" id="L01FG"></span>L01FG VEGF/VEGFR (vascular endothelial growth factor) inhibitors===
:L01FG01 [[Bevacizumab]]
:L01FG01 [[Bevacizumab]]
:L01FG02 [[Ramucirumab]]
:L01FG02 [[Ramucirumab]]


==={{anchor|L01FX}}L01FX Other monoclonal antibodies and antibody drug conjugates===
===<span class="anchor" id="L01FX"></span>L01FX Other monoclonal antibodies and antibody drug conjugates===
:L01FX01 [[Edrecolomab]]
:L01FX01 [[Edrecolomab]]
:L01FX02 [[Gemtuzumab ozogamicin]]
:L01FX02 [[Gemtuzumab ozogamicin]]
Line 338: Line 353:
:L01FX35 [[Datopotamab deruxtecan]]
:L01FX35 [[Datopotamab deruxtecan]]
:L01FX36 [[Patritumab deruxtecan]]
:L01FX36 [[Patritumab deruxtecan]]
:L01FX37 [[Linvoseltamab]]
:L01FX38 [[Ifinatamab deruxtecan]]
:L01FX39 [[Bemarituzumab]]


==={{anchor|L01FY}}L01FY Combinations of monoclonal antibodies and antibody drug conjugates===
===<span class="anchor" id="L01FY"></span>L01FY Combinations of monoclonal antibodies and antibody drug conjugates===
:L01FY01 [[Pertuzumab/trastuzumab|Pertuzumab and trastuzumab]]
:L01FY01 [[Pertuzumab/trastuzumab|Pertuzumab and trastuzumab]]
:L01FY02 [[Nivolumab/relatlimab|Nivolumab and relatlimab]]
:L01FY02 [[Nivolumab/relatlimab|Nivolumab and relatlimab]]
:L01FY03 [[Prolgolimab]] and [[nurulimab]]
:L01FY03 [[Prolgolimab]] and [[nurulimab]]


=={{anchor|L01X}}L01X Other antineoplastic agents==
==<span class="anchor" id="L01X"></span>L01X Other antineoplastic agents==


==={{anchor|L01XA}}L01XA Platinum compounds===
===<span class="anchor" id="L01XA"></span>L01XA Platinum compounds===
:L01XA01 [[Cisplatin]]
:L01XA01 [[Cisplatin]]
:L01XA02 [[Carboplatin]]
:L01XA02 [[Carboplatin]]
Line 353: Line 371:
:L01XA05 [[Polyplatillen]]
:L01XA05 [[Polyplatillen]]


==={{anchor|L01XB}}L01XB Methylhydrazines===
===<span class="anchor" id="L01XB"></span>L01XB Methylhydrazines===
:L01XB01 [[Procarbazine]]
:L01XB01 [[Procarbazine]]


==={{anchor|L01XD}}L01XD Sensitizers used in photodynamic/radiation therapy===
===<span class="anchor" id="L01XD"></span>L01XD Sensitizers used in photodynamic/radiation therapy===
:L01XD01 [[Porfimer sodium]]
:L01XD01 [[Porfimer sodium]]
:L01XD03 [[Methyl aminolevulinate]]
:L01XD03 [[Methyl aminolevulinate]]
Line 364: Line 382:
:L01XD07 [[Padeliporfin]]
:L01XD07 [[Padeliporfin]]


==={{anchor|L01XF}}L01XF Retinoids for cancer treatment===
===<span class="anchor" id="L01XF"></span>L01XF Retinoids for cancer treatment===
:L01XF01 [[Tretinoin]]
:L01XF01 [[Tretinoin]]
:L01XF02 [[Alitretinoin]]
:L01XF02 [[Alitretinoin]]
:L01XF03 [[Bexarotene]]
:L01XF03 [[Bexarotene]]


==={{anchor|L01XG}}L01XG Proteasome inhibitors===
===<span class="anchor" id="L01XG"></span>L01XG Proteasome inhibitors===
:L01XG01 [[Bortezomib]]
:L01XG01 [[Bortezomib]]
:L01XG02 [[Carfilzomib]]
:L01XG02 [[Carfilzomib]]
:L01XG03 [[Ixazomib]]
:L01XG03 [[Ixazomib]]


==={{anchor|L01XH}}L01XH Histone deacetylase (HDAC) inhibitors===
===<span class="anchor" id="L01XH"></span>L01XH Histone deacetylase (HDAC) inhibitors===
:L01XH01 [[Vorinostat]]
:L01XH01 [[Vorinostat]]
:L01XH02 [[Romidepsin]]
:L01XH02 [[Romidepsin]]
Line 383: Line 401:
:L01XH07 [[Resminostat]]
:L01XH07 [[Resminostat]]


==={{anchor|L01XJ}}L01XJ Hedgehog pathway inhibitors===
===<span class="anchor" id="L01XJ"></span>L01XJ Hedgehog pathway inhibitors===
:L01XJ01 [[Vismodegib]]
:L01XJ01 [[Vismodegib]]
:L01XJ02 [[Sonidegib]]
:L01XJ02 [[Sonidegib]]
:L01XJ03 [[Glasdegib]]
:L01XJ03 [[Glasdegib]]


==={{anchor|L01XK}}L01XK Poly (ADP-ribose) polymerase (PARP) inhibitors ===
===<span class="anchor" id="L01XK"></span>L01XK Poly (ADP-ribose) polymerase (PARP) inhibitors ===
:L01XK01 [[Olaparib]]
:L01XK01 [[Olaparib]]
:L01XK02 [[Niraparib]]
:L01XK02 [[Niraparib]]
Line 395: Line 413:
:L01XK05 [[Veliparib]]
:L01XK05 [[Veliparib]]
:L01XK06 [[Pamiparib]]
:L01XK06 [[Pamiparib]]
:L01XK07 [[Senaparib]]
:L01XK52 Niraparib and [[abiraterone]]
:L01XK52 Niraparib and [[abiraterone]]


==={{anchor|L01XL}}L01XL Antineoplastic cell and gene therapy ===
===<span class="anchor" id="L01XL"></span>L01XL Antineoplastic cell and gene therapy ===
:L01XL01 [[Sitimagene ceradenovec]]
:L01XL01 [[Sitimagene ceradenovec]]
:L01XL02 [[Talimogene laherparepvec]]
:L01XL02 [[Talimogene laherparepvec]]
Line 411: Line 430:
:L01XL12 [[Obecabtagene autoleucel]]
:L01XL12 [[Obecabtagene autoleucel]]


==={{anchor|L01XM}}L01XM Isocitrate dehydrogenase (IDH) inhibitors===
===<span class="anchor" id="L01XM"></span>L01XM Isocitrate dehydrogenase (IDH) inhibitors===
:L01XM01 [[Enasidenib]]
:L01XM01 [[Enasidenib]]
:L01XM02 [[Ivosidenib]]
:L01XM02 [[Ivosidenib]]
Line 417: Line 436:
:L01XM04 [[Vorasidenib]]
:L01XM04 [[Vorasidenib]]


==={{anchor|L01XU}}L01XU Other antineoplastic agents (cont.)===
===<span class="anchor" id="L01XU"></span>L01XU Other antineoplastic agents (cont.)===
:''Empty group''
:''Empty group''


==={{anchor|L01XX}}L01XX Other antineoplastic agents===
===<span class="anchor" id="L01XX"></span>L01XX Other antineoplastic agents===
:L01XX01 [[Amsacrine]]
:L01XX01 [[Amsacrine]]
:L01XX02 [[Asparaginase]]
:L01XX02 [[Asparaginase]]
Line 463: Line 482:
:L01XX85 [[Idroxioleic acid]]
:L01XX85 [[Idroxioleic acid]]
:L01XX86 [[Calaspargase pegol]]
:L01XX86 [[Calaspargase pegol]]
:L01XX87 [[Revumenib]]
:QL01XX91 [[Tigilanol tiglate]]
:QL01XX91 [[Tigilanol tiglate]]
:QL01XX92 [[Verdinexor]]
:QL01XX92 [[Verdinexor]]


==={{anchor|L01XY}}L01XY Combinations of antineoplastic agents===
===<span class="anchor" id="L01XY"></span>L01XY Combinations of antineoplastic agents===
:L01XY01 [[Cytarabine/daunorubicin|Cytarabine and daunorubicin]]
:L01XY01 [[Cytarabine/daunorubicin|Cytarabine and daunorubicin]]
:L01XY04 Bifikafusp alfa and onfekafusp alfa
:L01XY04 [[Bifikafusp alfa/onfekafusp alfa|Bifikafusp alfa and onfekafusp alfa]]


==References==
==References==

Latest revision as of 16:40, 28 December 2025

Template:Short description Template:ATC codes lead

L01A Alkylating agents

L01AA Nitrogen mustard analogues

L01AA01 Cyclophosphamide
L01AA02 Chlorambucil
L01AA03 Melphalan
L01AA05 Chlormethine
L01AA06 Ifosfamide
L01AA07 Trofosfamide
L01AA08 Prednimustine
L01AA09 Bendamustine
L01AA10 Melphalan flufenamide

L01AB Alkyl sulfonates

L01AB01 Busulfan
L01AB02 Treosulfan
L01AB03 Mannosulfan

L01AC Ethylene imines

L01AC01 Thiotepa
L01AC02 Triaziquone
L01AC03 Carboquone

L01AD Nitrosoureas

L01AD01 Carmustine
L01AD02 Lomustine
L01AD03 Semustine
L01AD04 Streptozocin
L01AD05 Fotemustine
L01AD06 Nimustine
L01AD07 Ranimustine
L01AD08 Uramustine

L01AG Epoxides

L01AG01 Etoglucid

L01AX Other alkylating agents

L01AX01 Mitobronitol
L01AX02 Pipobroman
L01AX03 Temozolomide
L01AX04 Dacarbazine

L01B Antimetabolites

L01BA Folic acid analogues

L01BA01 Methotrexate
L01BA03 Raltitrexed
L01BA04 Pemetrexed
L01BA05 Pralatrexate

L01BB Purine analogues

L01BB02 Mercaptopurine
L01BB03 Tioguanine
L01BB04 Cladribine
L01BB05 Fludarabine
L01BB06 Clofarabine
L01BB07 Nelarabine
QL01BB90 Rabacfosadine

L01BC Pyrimidine analogues

L01BC01 Cytarabine
L01BC02 Fluorouracil
L01BC03 Tegafur
L01BC04 Carmofur
L01BC05 Gemcitabine
L01BC06 Capecitabine
L01BC07 Azacitidine
L01BC08 Decitabine
L01BC09 Floxuridine
L01BC52 Fluorouracil, combinations
L01BC53 Tegafur, combinations
L01BC58 Decitabine, combinations
L01BC59 Trifluridine, combinations

L01C Plant alkaloids and other natural products

L01CA Vinca alkaloids and analogues

L01CA01 Vinblastine
L01CA02 Vincristine
L01CA03 Vindesine
L01CA04 Vinorelbine
L01CA05 Vinflunine
L01CA06 Vintafolide

L01CB Podophyllotoxin derivatives

L01CB01 Etoposide
L01CB02 Teniposide

L01CC Colchicine derivatives

L01CC01 Demecolcine

L01CD Taxanes

L01CD01 Paclitaxel
L01CD02 Docetaxel
L01CD03 Paclitaxel poliglumex
L01CD04 Cabazitaxel
L01CD51 Paclitaxel and encequidar

L01CE Topoisomerase 1 (TOP1) inhibitors

L01CE01 Topotecan
L01CE02 Irinotecan
L01CE03 Etirinotecan pegol
L01CE04 Belotecan

L01CX Other plant alkaloids and natural products

L01CX01 Trabectedin

L01D Cytotoxic antibiotics and related substances

L01DA Actinomycines

L01DA01 Dactinomycin

L01DB Anthracyclines and related substances

L01DB01 Doxorubicin
L01DB02 Daunorubicin
L01DB03 Epirubicin
L01DB04 Aclarubicin
L01DB05 Zorubicin
L01DB06 Idarubicin
L01DB07 Mitoxantrone
L01DB08 Pirarubicin
L01DB09 Valrubicin
L01DB10 Amrubicin
L01DB11 Pixantrone

L01DC Other cytotoxic antibiotics

L01DC01 Bleomycin
L01DC02 Plicamycin
L01DC03 Mitomycin
L01DC04 Ixabepilone
L01DC05 Utidelone

L01E Protein kinase inhibitors

L01EA BCR-ABL tyrosine kinase inhibitors

L01EA01 Imatinib
L01EA02 Dasatinib
L01EA03 Nilotinib
L01EA04 Bosutinib
L01EA05 Ponatinib
L01EA06 Asciminib

L01EB Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors

L01EB01 Gefitinib
L01EB02 Erlotinib
L01EB03 Afatinib
L01EB04 Osimertinib
L01EB05 Rociletinib
L01EB06 Olmutinib
L01EB07 Dacomitinib
L01EB08 Icotinib
L01EB09 Lazertinib
L01EB10 Mobocertinib
L01EB11 Aumolertinib
L01EB12 Firmonertinib

L01EC B-Raf serine-threonine kinase (BRAF) inhibitors

L01EC01 Vemurafenib
L01EC02 Dabrafenib
L01EC03 Encorafenib
L01EC04 Tovorafenib

L01ED Anaplastic lymphoma kinase (ALK) inhibitors

L01ED01 Crizotinib
L01ED02 Ceritinib
L01ED03 Alectinib
L01ED04 Brigatinib
L01ED05 Lorlatinib

L01EE Mitogen-activated protein kinase (MEK) inhibitors

L01EE01 Trametinib
L01EE02 Cobimetinib
L01EE03 Binimetinib
L01EE04 Selumetinib
L01EE05 Mirdametinib
L01EE06 Tunlametinib

L01EF Cyclin-dependent kinase (CDK) inhibitors

L01EF01 Palbociclib
L01EF02 Ribociclib
L01EF03 Abemaciclib

L01EG Mammalian target of rapamycin (mTOR) kinase inhibitors

L01EG01 Temsirolimus
L01EG02 Everolimus
L01EG03 Ridaforolimus
L01EG04 Sirolimus

L01EH Human epidermal growth factor receptor 2 (HER2) tyrosine kinase inhibitors

L01EH01 Lapatinib
L01EH02 Neratinib
L01EH03 Tucatinib
L01EH04 Zongertinib
L01EH05 Mifanertinib
L01EH06 Sevabertinib

L01EJ Janus-associated kinase (JAK) inhibitors

L01EJ01 Ruxolitinib
L01EJ02 Fedratinib
L01EJ03 Pacritinib
L01EJ04 Momelotinib

L01EK Vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitors

L01EK01 Axitinib
L01EK02 Cediranib
L01EK03 Tivozanib
L01EK04 Fruquintinib
L01EK05 Rivoceranib

L01EL Bruton's tyrosine kinase (BTK) inhibitors

L01EL01 Ibrutinib
L01EL02 Acalabrutinib
L01EL03 Zanubrutinib
L01EL04 Orelabrutinib
L01EL05 Pirtobrutinib
L01EL06 Tirabrutinib

L01EM Phosphatidylinositol-3-kinase (Pi3K) inhibitors

L01EM01 Idelalisib
L01EM02 Copanlisib
L01EM03 Alpelisib
L01EM04 Duvelisib
L01EM05 Parsaclisib
L01EM06 Inavolisib

L01EN Fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitors

L01EN01 Erdafitinib
L01EN02 Pemigatinib
L01EN03 Infigratinib
L01EN04 Futibatinib

L01EP Cellular-mesenchymal-epithelial transition factor (c-MET) kinase inhibitors

L01EP01 Capmatinib
L01EP02 Tepotinib
L01EP03 Savolitinib

L01EX Other protein kinase inhibitors

L01EX01 Sunitinib
L01EX02 Sorafenib
L01EX03 Pazopanib
L01EX04 Vandetanib
L01EX05 Regorafenib
L01EX06 Masitinib
L01EX07 Cabozantinib
L01EX08 Lenvatinib
L01EX09 Nintedanib
L01EX10 Midostaurin
L01EX11 Quizartinib
L01EX12 Larotrectinib
L01EX13 Gilteritinib
L01EX14 Entrectinib
L01EX15 Pexidartinib
L01EX18 Avapritinib
L01EX19 Ripretinib
L01EX22 Selpercatinib
L01EX23 Pralsetinib
L01EX24 Surufatinib
L01EX25 Umbralisib
L01EX26 Sitravatinib
L01EX27 Capivasertib
L01EX28 Repotrectinib
L01EX29 Vimseltinib
QL01EX90 Toceranib

L01F Monoclonal antibodies and antibody drug conjugates

L01FA CD20 (clusters of differentiation 20) inhibitors

L01FA01 Rituximab
L01FA02 Ofatumumab
L01FA03 Obinutuzumab

L01FB CD22 (clusters of differentiation 22) inhibitors

L01FB01 Inotuzumab ozogamicin
L01FB02 Moxetumomab pasudotox

L01FC CD38 (clusters of differentiation 38) inhibitors

L01FC01 Daratumumab
L01FC02 Isatuximab

L01FD HER2 (human epidermal growth factor receptor 2) inhibitors

L01FD01 Trastuzumab
L01FD02 Pertuzumab
L01FD03 Trastuzumab emtansine
L01FD04 Trastuzumab deruxtecan
L01FD05 Trastuzumab duocarmazine
L01FD06 Margetuximab
L01FD07 Zanidatamab

L01FE EGFR (epidermal growth factor receptor) inhibitors

L01FE01 Cetuximab
L01FE02 Panitumumab
L01FE03 Necitumumab

L01FF PD-1/PDL-1 (programmed cell death protein 1/ death ligand 1) inhibitors

L01FF01 Nivolumab
L01FF02 Pembrolizumab
L01FF03 Durvalumab
L01FF04 Avelumab
L01FF05 Atezolizumab
L01FF06 Cemiplimab
L01FF07 Dostarlimab
L01FF08 Prolgolimab
L01FF09 Tislelizumab
L01FF10 Retifanlimab
L01FF11 Sugemalimab
L01FF12 Serplulimab
L01FF13 Toripalimab
L01FF14 Camrelizumab
L01FF15 Envafolimab
L01FF16 Sasanlimab

L01FG VEGF/VEGFR (vascular endothelial growth factor) inhibitors

L01FG01 Bevacizumab
L01FG02 Ramucirumab

L01FX Other monoclonal antibodies and antibody drug conjugates

L01FX01 Edrecolomab
L01FX02 Gemtuzumab ozogamicin
L01FX03 Catumaxomab
L01FX04 Ipilimumab
L01FX05 Brentuximab vedotin
L01FX06 Dinutuximab beta
L01FX07 Blinatumomab
L01FX08 Elotuzumab
L01FX09 Mogamulizumab
L01FX10 Olaratumab
L01FX11 Bermekimab
L01FX12 Tafasitamab
L01FX13 Enfortumab vedotin
L01FX14 Polatuzumab vedotin
L01FX15 Belantamab mafodotin
L01FX16 Oportuzumab monatox
L01FX17 Sacituzumab govitecan
L01FX18 Amivantamab
L01FX19 Sabatolimab
L01FX20 Tremelimumab
L01FX21 Naxitamab
L01FX22 Loncastuximab tesirine
L01FX23 Tisotumab vedotin
L01FX24 Teclistamab
L01FX25 Mosunetuzumab
L01FX26 Mirvetuximab soravtansine
L01FX27 Epcoritamab
L01FX28 Glofitamab
L01FX29 Talquetamab
L01FX31 Zolbetuximab
L01FX32 Elranatamab
L01FX33 Tarlatamab
L01FX34 Odronextamab
L01FX35 Datopotamab deruxtecan
L01FX36 Patritumab deruxtecan
L01FX37 Linvoseltamab
L01FX38 Ifinatamab deruxtecan
L01FX39 Bemarituzumab

L01FY Combinations of monoclonal antibodies and antibody drug conjugates

L01FY01 Pertuzumab and trastuzumab
L01FY02 Nivolumab and relatlimab
L01FY03 Prolgolimab and nurulimab

L01X Other antineoplastic agents

L01XA Platinum compounds

L01XA01 Cisplatin
L01XA02 Carboplatin
L01XA03 Oxaliplatin
L01XA04 Satraplatin
L01XA05 Polyplatillen

L01XB Methylhydrazines

L01XB01 Procarbazine

L01XD Sensitizers used in photodynamic/radiation therapy

L01XD01 Porfimer sodium
L01XD03 Methyl aminolevulinate
L01XD04 Aminolevulinic acid
L01XD05 Temoporfin
L01XD06 Efaproxiral
L01XD07 Padeliporfin

L01XF Retinoids for cancer treatment

L01XF01 Tretinoin
L01XF02 Alitretinoin
L01XF03 Bexarotene

L01XG Proteasome inhibitors

L01XG01 Bortezomib
L01XG02 Carfilzomib
L01XG03 Ixazomib

L01XH Histone deacetylase (HDAC) inhibitors

L01XH01 Vorinostat
L01XH02 Romidepsin
L01XH03 Panobinostat
L01XH04 Belinostat
L01XH05 Entinostat
L01XH06 Tucidinostat
L01XH07 Resminostat

L01XJ Hedgehog pathway inhibitors

L01XJ01 Vismodegib
L01XJ02 Sonidegib
L01XJ03 Glasdegib

L01XK Poly (ADP-ribose) polymerase (PARP) inhibitors

L01XK01 Olaparib
L01XK02 Niraparib
L01XK03 Rucaparib
L01XK04 Talazoparib
L01XK05 Veliparib
L01XK06 Pamiparib
L01XK07 Senaparib
L01XK52 Niraparib and abiraterone

L01XL Antineoplastic cell and gene therapy

L01XL01 Sitimagene ceradenovec
L01XL02 Talimogene laherparepvec
L01XL03 Axicabtagene ciloleucel
L01XL04 Tisagenlecleucel
L01XL05 Ciltacabtagene autoleucel
L01XL06 Brexucabtagene autoleucel
L01XL07 Idecabtagene vicleucel
L01XL08 Lisocabtagene maraleucel
L01XL09 Tabelecleucel
L01XL10 Nadofaragene firadenovec
L01XL11 Lifileucel
L01XL12 Obecabtagene autoleucel

L01XM Isocitrate dehydrogenase (IDH) inhibitors

L01XM01 Enasidenib
L01XM02 Ivosidenib
L01XM03 Olutasidenib
L01XM04 Vorasidenib

L01XU Other antineoplastic agents (cont.)

Empty group

L01XX Other antineoplastic agents

L01XX01 Amsacrine
L01XX02 Asparaginase
L01XX03 Altretamine
L01XX05 Hydroxycarbamide
L01XX07 Lonidamine
L01XX08 Pentostatin
L01XX10 Masoprocol
L01XX11 Estramustine
L01XX16 Mitoguazone
L01XX18 Tiazofurine
L01XX23 Mitotane
L01XX24 Pegaspargase
L01XX27 Arsenic trioxide
L01XX29 Denileukin diftitox
L01XX33 Celecoxib
L01XX35 Anagrelide
L01XX36 Oblimersen
L01XX40 Omacetaxine mepesuccinate
L01XX41 Eribulin
L01XX44 Aflibercept
L01XX46 Olaparib
L01XX52 Venetoclax
L01XX53 Vosaroxin
L01XX57 Plitidepsin
L01XX58 Epacadostat
L01XX66 Selinexor
L01XX67 Tagraxofusp
L01XX69 Lurbinectedin
L01XX72 Tazemetostat
L01XX73 Sotorasib
L01XX74 Belzutifan
L01XX75 Tebentafusp
L01XX77 Adagrasib
L01XX78 Navitoclax
L01XX79 Eflornithine
L01XX80 Imetelstat
L01XX81 Nirogacestat
L01XX82 Darinaparsin
L01XX83 Para-toluenesulfonamide
L01XX84 Pelabresib
L01XX85 Idroxioleic acid
L01XX86 Calaspargase pegol
L01XX87 Revumenib
QL01XX91 Tigilanol tiglate
QL01XX92 Verdinexor

L01XY Combinations of antineoplastic agents

L01XY01 Cytarabine and daunorubicin
L01XY04 Bifikafusp alfa and onfekafusp alfa

References

<templatestyles src="Reflist/styles.css" />

Script error: No such module "Check for unknown parameters".

Template:Intracellular chemotherapeutic agents Template:Extracellular chemotherapeutic agents

Retrieved from "http://debianws.lexgopc.com/wiki143/index.php?title=ATC_code_L01&oldid=5280888"